JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Establishing a glycolysis-linked multigene prognostic signature in lung adenocarcinoma: a multicenter integrative approach

  • 0Department of Radiotherapy Technology Center, Harbin Medical University Cancer Hospital, Harbin, China.
Journal of Thoracic Disease +

|

September 15, 2025

|

September 15, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

A new 14-gene glycolysis metabolism prognostic signature (14GM-PS) accurately predicts survival in lung adenocarcinoma (LUAD) patients. This tool aids in personalized treatment decisions for LUAD, improving patient outcomes.

Area Of Science

  • Oncology
  • Genomics
  • Bioinformatics

Background

  • Lung adenocarcinoma (LUAD) has a high mortality rate, with many early-stage patients experiencing recurrence after surgery.
  • Existing prognostic markers for LUAD lack reproducibility and consistent performance due to small sample sizes and technical biases.
  • There is an urgent need for reliable prognostic markers to guide clinical decisions and improve outcomes for LUAD patients.

Purpose Of The Study

  • To develop a robust, function-derived gene signature for predicting prognosis in lung adenocarcinoma (LUAD).
  • To address limitations of existing LUAD prognostic signatures through a multicenter integrative analysis approach.
  • To identify reliable molecular markers for guiding clinical decisions and enhancing patient outcomes in LUAD.

Main Methods

  • Utilized gene expression and clinical data from 1,238 curatively resected LUAD patients across 11 public datasets.
  • Employed a meta-discovery dataset of 665 patients to identify prognostic genes from a functional perspective, focusing on glycolysis.
  • Developed a 14-gene glycolysis metabolism prognostic signature (14GM-PS) using single-sample gene set enrichment analysis.

Main Results

  • The 14GM-PS demonstrated significant prognostic performance in two independent validation datasets (log-rank P<0.001 and P=0.004).
  • Multivariate Cox analysis confirmed the 14GM-PS as an independent predictor of LUAD patient prognosis.
  • A nomogram incorporating 14GM-PS and clinicopathological factors improved prognostic accuracy, showing associations with hypoxia, proliferation, stemness, and immune scores.

Conclusions

  • The multicenter study validated the accuracy and stability of the 14GM-PS for predicting LUAD patient prognosis.
  • The 14GM-PS shows potential as a genomic tool for guiding individualized treatment strategies in LUAD.
  • Further prospective clinical validation is necessary before the 14GM-PS can be implemented in clinical practice.

Keywords: